Patrik Jonsson
President, Lilly International
“There will be no gating of launches either.”
“We continue to see TRx grow for MOUNJARO even after the launch of generic semaglutide...driven by the strong differentiation we have with the superiority data.”
Patrik Jonsson
One-line summary: Runs Lilly International; source on ex-US supply adequacy and generic-semaglutide competitive dynamics.
What they're known for
Brief factual context — fill in.
Why they matter to stock-market
Why this person's claims are tracked here — fill in.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
-
On glp1-injectable-supply-chain-bottleneck:
"There will be no gating of launches either." — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
-
On glp1-injectable-supply-chain-bottleneck:
"We continue to see TRx grow for MOUNJARO even after the launch of generic semaglutide...driven by the strong differentiation we have with the superiority data." — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
Sources
Related
Cross-links — fill in.